One such biomarker, FGF-21, shows promising potential in predicting NAFLD in individuals with Type 2 Diabetes Mellitus (T2DM) due to its high sensitivity and specificity compared to other markers [87]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.